PharmacoEconomics

Introduction to the Pharmacoeconomics of Herbal Medicines
pp. 1-7(7)
Authors: De Smet P.A.G.M.; Bonsel G.; Van der Kuy A.; Hekster Y.A.; Pronk M.H.; Brorens M.J.A.; Lockefeer J.H.M.; Nuijten M.J.C.

Economic Issues in the Prevention of Vertical Transmission of HIV
pp. 9-22(14)
Authors: Ades A.E.; Ratcliffe J.; Gibb D.M.; Sculpher M.J.

Social Phobia: Epidemiology and Cost of Illness
pp. 23-32(10)
Authors: Lipsitz J.D.; Schneier F.R.

A Review of Alternative Approaches to Healthcare Resource Allocation
pp. 33-43(11)
Authors: Petrou S.; Wolstenholme J.

Long Term Treatment of Multiple Sclerosis with Interferon- May Be Cost Effective
pp. 45-53(9)
Authors: Kendrick M.; Johnson K.I.

Using Economic Evaluations to Make Formulary Coverage Decisions: So Much for Guidelines
pp. 55-62(8)
Authors: Anis A.H.; Gagnon Y.

Health-Related Quality of Life in Asymptomatic Patients with HIV: Evaluation of the SF-36 Health Survey in Italian Patients
pp. 63-72(10)
Authors: Arpinelli F.; Visona G.; Bruno R.; Decarli G.; Apolone G.

The Impact of Pituitary Adenoma on Morbidity: Increased Sick Leave and Disability Retirement in a Cross-Sectional Analysis of Swedish National Data
pp. 73-81(9)
Authors: Jonsson B.; Nilsson B.

Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina: A French Sub-Study of the ESSENCE Trial
pp. 83-89(7)
Authors: Detournay B.; Huet X.; Fagnani F.; Montalescot G.